Eli Lilly's Zepbound Anticipates Approval in Japan by Mid-2025
核心洞察
Eli Lilly expects its weight-loss drug Zepbound to receive regulatory approval in Japan by mid-2025, according to CEO David Ricks.
Zepbound's approval would allow it to compete in Japan's growing weight-loss market, challenging Novo Nordisk's Wegovy.
Already approved in the U.S. and Europe, Zepbound is a key element in Eli Lilly's expanding obesity (搜索) treatment offerings.
Eli Lilly anticipates that its weight-loss drug, Zepbound, will gain regulatory clearance in Japan by mid-2025, positioning it to compete in the country's expanding weight-loss market. This projection was confirmed by Eli Lilly CEO David Ricks in an interview, reinforcing the company's confidence in the ongoing regulatory process.
David Ricks stated, "We are confident the regulatory process is headed forward and we expect approval by the middle of next year." Once approved, Zepbound will enter a market already served by Novo Nordisk's Wegovy, which has been available in Japan since the previous year.
Zepbound has already secured approval in the United States and Europe and is considered a crucial component of Eli Lilly's growing portfolio of obesity (搜索) treatments. The company is making substantial investments in the global development of its obesity-related medications, recognizing their significant revenue-generating potential.
The announcement of the expected approval in Japan led to a 1.81% increase in Eli Lilly's stock value, signaling positive investor sentiment.